Evaluation of Transparency to Improve Good Governance in Pharmaceutical Regulatory Sector of Iran

Background: Improving good governance in the pharmaceutical sector is a valuable priority for improving access to essential medicines. Transparency as a means for good governance was the focus of this study. The objective was to evaluate different sectors of the pharmaceutical regulatory sector of I...

Full description

Bibliographic Details
Main Authors: Yasaman Herandi, Shekoufeh Nikfar, Hossein Bouzarjomehri, Akbar Abdollahiasl
Format: Article
Language:English
Published: Shahid Sadoughi University of Medical Sciences 2020-09-01
Series:Journal of Evidence Based Health Policy, Management & Economics
Subjects:
Online Access:http://jebhpme.ssu.ac.ir/article-1-284-en.html
id doaj-1df81e7ab8f0465493aa412c00a79d24
record_format Article
spelling doaj-1df81e7ab8f0465493aa412c00a79d242020-11-25T03:27:52ZengShahid Sadoughi University of Medical SciencesJournal of Evidence Based Health Policy, Management & Economics2538-50702538-47162020-09-0143197208Evaluation of Transparency to Improve Good Governance in Pharmaceutical Regulatory Sector of IranYasaman Herandi0Shekoufeh Nikfar1Hossein Bouzarjomehri2Akbar Abdollahiasl3 Pharmacoeconomics and Pharmaceutical Administration Department, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran Pharmacoeconomics and Pharmaceutical Administration Department, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran Student Research Committee, Iran University of Medical Sciences, Tehran, Iran Pharmacoeconomics and Pharmaceutical Administration Department, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran Background: Improving good governance in the pharmaceutical sector is a valuable priority for improving access to essential medicines. Transparency as a means for good governance was the focus of this study. The objective was to evaluate different sectors of the pharmaceutical regulatory sector of Iran from the aspect of transparency. Awareness of the current situation may assist policymakers in making the right decisions. Methods: The aim of this methodology was to present only quantitative measurement but to gather qualitative information as well. The study was carried from November 2016 to July 2017. The questionnaires of the assessment instrument, which the World Health Organization (WHO) produced for measuring transparency in the public pharmaceutical sector, was used. The interviewees were among managers and staff at different levels of the Food and Drug Administration (IFDA) of Iran and its clients. Results: Medicines registration and distribution of medicines’ scores in the 10-point rating system means that they are minimally vulnerable to corruption. Besides, medicine promotion control and procurement of medical products got an acceptable score, which means that they are marginally vulnerable to corruption. On the other hand, qualitative findings and observation of the evidence presented by key informants proved the sufficient legal capacity for transparency in almost all sections. The controversial issue was the ‘conflict of interests,’ which was not anticipated in some cases. Conclusion: It is valuable to know if Iran’s medicine regulatory sector is transparent In order to improve good governance, transparency should be maximized in all sectors, and this is possible by implementing mechanized actions and online tools.http://jebhpme.ssu.ac.ir/article-1-284-en.htmlpharmacy administrationdrug and narcotic controlevaluationpharmacoeconomicsiran
collection DOAJ
language English
format Article
sources DOAJ
author Yasaman Herandi
Shekoufeh Nikfar
Hossein Bouzarjomehri
Akbar Abdollahiasl
spellingShingle Yasaman Herandi
Shekoufeh Nikfar
Hossein Bouzarjomehri
Akbar Abdollahiasl
Evaluation of Transparency to Improve Good Governance in Pharmaceutical Regulatory Sector of Iran
Journal of Evidence Based Health Policy, Management & Economics
pharmacy administration
drug and narcotic control
evaluation
pharmacoeconomics
iran
author_facet Yasaman Herandi
Shekoufeh Nikfar
Hossein Bouzarjomehri
Akbar Abdollahiasl
author_sort Yasaman Herandi
title Evaluation of Transparency to Improve Good Governance in Pharmaceutical Regulatory Sector of Iran
title_short Evaluation of Transparency to Improve Good Governance in Pharmaceutical Regulatory Sector of Iran
title_full Evaluation of Transparency to Improve Good Governance in Pharmaceutical Regulatory Sector of Iran
title_fullStr Evaluation of Transparency to Improve Good Governance in Pharmaceutical Regulatory Sector of Iran
title_full_unstemmed Evaluation of Transparency to Improve Good Governance in Pharmaceutical Regulatory Sector of Iran
title_sort evaluation of transparency to improve good governance in pharmaceutical regulatory sector of iran
publisher Shahid Sadoughi University of Medical Sciences
series Journal of Evidence Based Health Policy, Management & Economics
issn 2538-5070
2538-4716
publishDate 2020-09-01
description Background: Improving good governance in the pharmaceutical sector is a valuable priority for improving access to essential medicines. Transparency as a means for good governance was the focus of this study. The objective was to evaluate different sectors of the pharmaceutical regulatory sector of Iran from the aspect of transparency. Awareness of the current situation may assist policymakers in making the right decisions. Methods: The aim of this methodology was to present only quantitative measurement but to gather qualitative information as well. The study was carried from November 2016 to July 2017. The questionnaires of the assessment instrument, which the World Health Organization (WHO) produced for measuring transparency in the public pharmaceutical sector, was used. The interviewees were among managers and staff at different levels of the Food and Drug Administration (IFDA) of Iran and its clients. Results: Medicines registration and distribution of medicines’ scores in the 10-point rating system means that they are minimally vulnerable to corruption. Besides, medicine promotion control and procurement of medical products got an acceptable score, which means that they are marginally vulnerable to corruption. On the other hand, qualitative findings and observation of the evidence presented by key informants proved the sufficient legal capacity for transparency in almost all sections. The controversial issue was the ‘conflict of interests,’ which was not anticipated in some cases. Conclusion: It is valuable to know if Iran’s medicine regulatory sector is transparent In order to improve good governance, transparency should be maximized in all sectors, and this is possible by implementing mechanized actions and online tools.
topic pharmacy administration
drug and narcotic control
evaluation
pharmacoeconomics
iran
url http://jebhpme.ssu.ac.ir/article-1-284-en.html
work_keys_str_mv AT yasamanherandi evaluationoftransparencytoimprovegoodgovernanceinpharmaceuticalregulatorysectorofiran
AT shekoufehnikfar evaluationoftransparencytoimprovegoodgovernanceinpharmaceuticalregulatorysectorofiran
AT hosseinbouzarjomehri evaluationoftransparencytoimprovegoodgovernanceinpharmaceuticalregulatorysectorofiran
AT akbarabdollahiasl evaluationoftransparencytoimprovegoodgovernanceinpharmaceuticalregulatorysectorofiran
_version_ 1724586654885216256